ARTICLE SUMMARY:
SetPoint Medical has developed a bioelectronic medicine to treat chronic inflammation-mediated diseases of the immune system, such as rheumatoid arthritis and Crohn’s disease. Unlike neuromodulation therapies that have come before, SetPoint elicits a molecular, rather than functional, reaction from the body, restoring the regulatory signal that tells the body to downregulate pro-inflammatory cytokines.
In the recent investor presentations of major medical device companies, neuromodulation has been cast as a platform for growth into billion-dollar-plus markets currently dominated by pharmaceutical treatments.
